Cochlear Ltd. (ASX: COH) is a global leader in implantable hearing solutions, including cochlear implants and bone conduction systems. With strong clinical outcomes, proprietary R&D, and extensive audiologist partnerships, Cochlear supports long-term hearing restoration for both adults and children. The company benefits from aging demographics, market expansion, and post-pandemic procedural recovery. It offers investors resilient medtech exposure and growth from innovation in auditory healthcare.
Nieuwste artikelen over aandelen